Bcl-2 protein in diffuse large B-cell lymphoma

Proteína Bcl-2 em linfoma difuso de grandes células B

LETTER TO THE EDITOR

Bcl-2 protein in diffuse large B-cell lymphoma

Proteína Bcl-2 em linfoma difuso de grandes células B

Viroj Wiwanitkit

MD, PhD. Professor, Wiwanitkit House, Bangkhae, Bangkok, Thailand

^{Address for correspondence}

Dear Editor,

I read the recently published paper on Bcl-2 with great interest. ¹ Hallack Neto et al. concluded that "Bcl-2 protein was expressed in 37% of the high-risk DLBCL patients, without any difference between the ABC-like DLBCL and GCB-like DLBCL cases. ¹" Indeed, the clinical value of determining Bcl-2 in B-cell lymphoma is still controversial. However, there are some problems in this work. The retrospective cohort design is not a common approach. There is also no risk classification from the analysis. The small number of subjects in this work might not be statistically acceptable for any conclusion.

Date of first submission: June 18, 2010

Last received: June 18, 2010

Accepted: November 3, 2010

Sources of funding: None

Conflict of interest: None

• ¹
  Hallack Neto AE, Siqueira SA, Dulley FL, et al. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma. São Paulo Med J. 2010;128(1):14-7.

Publication Dates

• Publication in this collection
  10 Mar 2011
• Date of issue
  Jan 2011